Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature

被引：11

作者：

Gooch, Megan E. ^{[1
]}

Nader, Kamyar ^{[2
]}

Kubicek, Gregory J. ^{[3
]}

Somer, Robert A. ^{[2
]}

机构：

[1] Cooper Univ Hosp, Dept Internal Med, 401 Haddon Ave,E&R Bldg,Third Floor, Camden, NJ 08103 USA

[2] MD Anderson Canc Ctr Cooper, Dept Hematol & Oncol, Camden, NJ USA

[3] MD Anderson Canc Ctr Cooper, Dept Radiat Oncol, Camden, NJ USA

来源：

CLINICAL GENITOURINARY CANCER | 2016年 / 14卷 / 04期

关键词：

Brain metastasis; Clear-cell mRCC; Pazopanib; Renal cell carcinoma; Tyrosine kinase inhibitors; TYROSINE KINASE INHIBITORS; SORAFENIB; SUNITINIB; BREAST; RESISTANCE; EFFICACY; PROTEIN; GROWTH;

D O I：

10.1016/j.clgc.2016.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The exact mechanism of intracranial metastasis in renal cell carcinoma (RCC) is unknown; however, vascular endothelial growth factor expression may contribute to formation of cerebral lesions. Brain metastasis usually is an exclusion criteria in clinical trials, and data are scarce on effective treatments of brain metastasis in patients with RCC. Limited retrospective analysis has shown activity of tyrosine kinase inhibitors, such as sunitinib and sorafenib, in treating brain metastasis. Pazopanib potentially can be used in adjunct to local therapy for treatment of brain metastasis in patients with RCC; however, more data and research are needed in this area. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：E401 / E404

页数：4

共 32 条

[1] Inactivation of the tumor suppressor WTX in a subset of pediatric tumors [J].

Akhavanfard, Sara ;

Vargas, Sara O. ;

Han, Moonjoo ;

Nitta, Mai ;

Chang, Clarice B. ;

Le, Long P. ;

Fazlollahi, Ladan ;

Quan Nguyen ;

Ma, Yunqing ;

Cosper, Arjola ;

Dias-Santagata, Dora ;

Han, Jae Y. ;

Bergethon, Kristin ;

Borger, Darrell R. ;

Ellisen, Leif W. ;

Pomeroy, Scott L. ;

Haber, Daniel A. ;

Iafrate, A. John ;

Rivera, Miguel N. .

GENES CHROMOSOMES & CANCER, 2014, 53 (01) :67-77

[2]

[Anonymous], P AM SOC CLIN ONCOL

[3]

[Anonymous], CANCER

[4] Intracerebral hemorrhage [J].

Badjatia, N ;

Rosand, J .

NEUROLOGIST, 2005, 11 (06) :311-324

[5] Distribution of metastatic sites in renal cell carcinoma: a population-based analysis [J].

Bianchi, M. ;

Sun, M. ;

Jeldres, C. ;

Shariat, S. F. ;

Trinh, Q. -D. ;

Briganti, A. ;

Tian, Z. ;

Schmitges, J. ;

Graefen, M. ;

Perrotte, P. ;

Menon, M. ;

Montorsi, F. ;

Karakiewicz, P. I. .

ANNALS OF ONCOLOGY, 2012, 23 (04) :973-980

[6] The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients [J].

Breedveld, P ;

Pluim, D ;

Cipriani, G ;

Wielinga, P ;

van Tellingen, O ;

Schinkel, AH ;

Schellens, JHM .

CANCER RESEARCH, 2005, 65 (07) :2577-2582

[7] Renal-cell carcinoma - Molecular pathways and therapies [J].

Brugarolas, James .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :185-187

[8] What is the risk of intracranial bleeding during anti-VEGF therapy? [J].

Carden, Craig P. ;

Larkin, James M. G. ;

Rosenthal, Mark A. .

NEURO-ONCOLOGY, 2008, 10 (04) :624-630

[9]

DeVita V., 2008, Cancer: Principles and Practice of Oncology, V8th

[10] Sunitinib in Metastatic Renal Cell Carcinoma Patients With Brain Metastases [J].

Gore, Martin E. ;

Hariharan, Subramanian ;

Porta, Camillo ;

Bracarda, Sergio ;

Hawkins, Robert ;

Bjarnason, Georg A. ;

Oudard, Stephane ;

Lee, Se-Hoon ;

Carteni, Giacomo ;

Nieto, Alejandra ;

Yuan, Jinyu ;

Szczylik, Cezary .

CANCER, 2011, 117 (03) :501-509

← 1 2 3 4 →